News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

Celldex vaccine improves long-term brain cancer survival in study

Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 Amazing results.  25% of patients with recurrent gbm alive after 2 years compared with NONE in the control group!  The FDA should try to get this approved as soon as possible. We shouldn't have to wait years for another study.


Posted on: 11/20/2015

Celldex vaccine improves long-term brain cancer survival in study
New data from a midstage trial show that Celldex Therapeutics Inc's experimental brain cancer vaccine, combined with standard therapy, continues to improve chances of survival for patients with recurrent cancer.
The updated results sent shares of Celldex up $1.74, or 12 percent, to $16.23 on the Nasdaq.
The therapy, designed to enlist the body's immune system to fight glioblastoma multiforme (GBM), showed that 25 percent of patients given Celldex's Rintega along with Roche Holding AG's Avastin were alive after two years, compared with no survivors in the group of patients given only Avastin.
Results from the 73-patient trial were presented on Friday at the Annual Scientific Meeting of the Society for Neuro-Oncology.
"The long-term survival benefit observed in this study is unprecedented," Dr. David Reardon, clinical director at Dana-Farber Cancer Institute's Center for Neuro-Oncology, and the study's lead investigator said in a statement.
Rintega, which was granted breakthrough therapy designation by the U.S. Food and Drug Administration last year, targets a specific genetic mutation that occurs in about 30 percent of GBM tumors.
Currently, the median survival for such patients with recurrent GBM is about nine months, Celldex said.
The latest trial results showed that 32 percent of patients treated with Rintega, also known as rindopepimut, and Avastin, or bevacizumab, were alive after 18 months, compared with 13 percent of those given only Avastin.
Celldex has previously reported that the trial met its main goal of showing that Rintega patients were more likely to be alive after six months without their cancer worsening.
Celldex said it expects to report early next year interim results from a study of Rintega in patients with newly diagnosed GBM.
Read more at Reuters


Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557